Allergan Stock To Go Ex-dividend Monday (AGN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for Allergan (NYSE: AGN) is Monday, November 19, 2012. Owners of shares as of market close today will be eligible for a dividend of 5 cents per share. At a price of $87.73 as of 9:30 a.m. ET, the dividend yield is 0.2%.

The average volume for Allergan has been 1.7 million shares per day over the past 30 days. Allergan has a market cap of $26.8 billion and is part of the health care sector and drugs industry. Shares are up 1.6% year to date as of the close of trading on Thursday.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company has a P/E ratio of 26.1, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Allergan Ratings Report.

See our dividend calendar or top-yielding stocks list.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)